Fulgent Genetics, Inc.
Every calculator, already run for FLGT
Open the full toolkit →You have the numbers on FLGT. Get the argument.
A written report on which of these readings actually decide the outcome for Fulgent Genetics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
1 analysts covering FLGTOwnership & short interest
About Fulgent Genetics, Inc.
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencaps…
FLGT — frequently asked
Is FLGT a buy right now?
Wall Street's consensus rating on Fulgent Genetics, Inc. is Hold across 1 analysts, with a mean price target of $19.00 (+3% vs. the current $18.53). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Compare Fulgent Genetics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Fulgent Genetics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full FLGT research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Fulgent Genetics, Inc., in minutes. 3 free reports included with every account — no credit card required.